FTO and familial pancreatic carcinoma: This study not only further confirmed suppression of the immune evasion of AML through the FTO/m6A/LILRB4 axis in vitro and in vivo but also identified that these inhibitors possess therapeutic potential in treating solid tumors, including glioblastoma, breast cancer, and pancreatic cancer.